Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jan 15;8(5):478–489. doi: 10.1002/sctm.18-0178

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 The Authors. stem cells translational medicine published by Wiley Periodicals, Inc. on behalf of AlphaMed Press

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Results of different carrier gel treatments in a mechanical corneal wound model in rats in vivo. (A): Fluorescein staining of corneas examined under blue light revealed that MSC‐S delivered in HA/CS yielded smaller wound areas 1 day after treatment compared to saline, MSC‐S in Systane gel (0.4% polyethylene glycol 400% and 0.3% propylene glycol) and BSA in HA/CS. Each treatment was applied right after the injury on day 0. (B): Quantification of fluorescently stained wound areas showed that the MSC‐S in HA/CS treatment led to a statistically significantly smaller wound area at 24 hours compared to all other treatments (*, p < .05). Abbreviations: BSA, bovine serum albumin; CS, chondroitin sulfate; HA, hyaluronic acid; MSC‐S, mesenchymal stem cells secretome.